Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesChange in Working CapitalExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet Equity Issued and RepurchasedNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and Equipment
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVSEF) Amortization (2020 - 2024)

Historic Amortization for Novartis Ag (NVSEF) over the last 5 years, with Q4 2024 value amounting to $1.2 billion.

  • Novartis Ag's Amortization rose 760666.67% to $1.2 billion in Q4 2024 from the same period last year, while for Dec 2024 it was $1.2 billion, marking a year-over-year increase of 760666.67%. This contributed to the annual value of $1.2 billion for FY2024, which is 760666.67% up from last year.
  • As of Q4 2024, Novartis Ag's Amortization stood at $1.2 billion, which was up 760666.67% from $1.0 billion recorded in Q3 2024.
  • In the past 5 years, Novartis Ag's Amortization registered a high of $1.2 billion during Q4 2024, and its lowest value of $15.0 million during Q4 2023.
  • In the last 4 years, Novartis Ag's Amortization had a median value of $318.5 million in 2020 and averaged $490.8 million.
  • Its Amortization has fluctuated over the past 5 years, first tumbled by 5504.59% in 2021, then soared by 760666.67% in 2024.
  • Over the past 4 years, Novartis Ag's Amortization (Quarter) stood at $218.0 million in 2020, then plummeted by 55.05% to $98.0 million in 2021, then tumbled by 84.69% to $15.0 million in 2023, then soared by 7606.67% to $1.2 billion in 2024.
  • Its Amortization was $1.2 billion in Q4 2024, compared to $1.0 billion in Q3 2024 and $419.0 million in Q2 2024.